Aerogen
Aerogen is an Ireland-based medical device company that develops vibrating mesh nebuliser technology for acute care aerosol drug delivery to hospitals, ICUs, and ventilator OEMs across more than 80 countries. It sells the Aerogen Solo platform, supports it with over 300 patents and clinical publications, and is extending into drug-device combinations through its Aerogen Pharma subsidiary.
- Company typePrivate
- Founded1998
- HeadquartersGalway, Ireland
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Aerogen does
Aerogen is a privately held Irish medical device company founded in 1997-1998 by John Power in Galway, Ireland, that develops vibrating mesh nebuliser technology for high-performance aerosol drug delivery in acute care settings. Its core product platform, centered on the Aerogen Solo single-patient-use nebuliser, delivers approximately four times more medication to the lungs than conventional jet nebulisers across invasive mechanical ventilation, non-invasive ventilation, high-flow therapy, and self-ventilating patient modes, supported by more than 300 international patents and 300 peer-reviewed publications. The company is the designated partner of choice for the world's leading mechanical ventilator manufacturers and distributes through direct sales in major markets plus an exclusive distributor network across more than 80 countries, with manufacturing in Galway and Shannon (Ireland) and regional hubs in Chicago, New Delhi, Tokyo, Düsseldorf, and Dubai.
Aerogen generates revenue primarily through hardware sales of its nebuliser devices and accessories (Solo, Ultra, Go, Pro, CNTS, controllers), with US channel access secured through GPO contracts with Premier and Vizient. A complementary specialty pharmaceutical revenue stream is being built through Aerogen Pharma, a US-based clinical-stage subsidiary developing inhaled drug and biologic-device combinations, including neonatal respiratory distress syndrome surfactant delivery in partnership with the Bill & Melinda Gates Foundation and Nuance Pharma in China. The company serves acute care hospitals and ICUs as its primary end market, with secondary segments in emergency and respiratory care, neonatal care, and ventilator OEMs as integration partners. Customers include leading hospital systems and GPOs, while collaborations with CanSinoBIO (world's first inhaled COVID-19 vaccine), Synairgen (inhaled interferon-beta), UNICEF, Tyndall National Institute, and CÚRAM demonstrate a broader ecosystem of public health, vaccine delivery, and academic research partnerships.
Aerogen firmographics
Firmographics- Name
- Aerogen
- Legal name
- Aerogen Ltd
- Website
- https://aerogen.com
- Company type
- Private
- Founded year
- 1998
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Aerogen is an Ireland-based medical device company that develops vibrating mesh nebuliser technology for acute care aerosol drug delivery to hospitals, ICUs, and ventilator OEMs across more than 80 countries. It sells the Aerogen Solo platform, supports it with over 300 patents and clinical publications, and is extending into drug-device combinations through its Aerogen Pharma subsidiary.
- Ownership category
- akta.pro rank
Aerogen industry classification
Industry- Product category
- Respiratory Care Medical Devices
- NAICS
- Medical Equipment and Supplies Manufacturing (3391), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Nebulizers & Aerosol Drug Delivery Systems (HLAHAIAJ)
- akta.pro secondary industries
- Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories) (HLAHAGAE), Noninvasive Ventilation Interfaces & Consumables (Masks, Tubing, Humidifiers, Filters) (HLAHAGAG)
Keywords
Where Aerogen is headquartered
LocationHeadquarters
- HQ city
- Galway
- HQ country
- Ireland
- HQ region
- Europe
Offices7 records
Markets served
Aerogen business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Medical Device Sales - Nebulisers: Aerogen generates revenue through the sale of its vibrating mesh nebuliser devices including Aerogen Solo, Aerogen Ultra, Aerogen Go, and related accessories. Products are sold directly and through distributor networks globally to healthcare facilities.
- Aerogen Pharma - Drug-Device Combinations: Aerogen Pharma, a US-based clinical-stage specialty pharmaceutical company, is developing inhaled drug/biologic and device combination products including treatments for neonatal respiratory distress syndrome.
Go-to-market motion2 records
Distribution channels6 records
Marketing channels5 records
Aerogen product offering
Product offeringCore offering
Aerogen designs, manufactures, and sells vibrating mesh nebuliser devices used by hospitals and intensive care units for high-performance aerosol drug delivery across the full respiratory care journey (invasive mechanical ventilation, non-invasive ventilation, high-flow therapy, and self-ventilating patients). Its wholly owned subsidiary Aerogen Pharma develops inhaled drug/device combination products targeting acute and neonatal respiratory conditions.
Product overview
Aerogen offers a portfolio of vibrating mesh nebulizer products for acute care aerosol drug delivery. The core product is the Aerogen Solo, a single-patient-use vibrating mesh nebulizer that can be used throughout a patient's entire respiratory journey across different ventilation modes (IMV, NIV, HF, and self-ventilating). Supporting products include the Aerogen Ultra handheld inhalation device, Aerogen Go, Aerogen Pro, the Aerogen Continuous Nebulisation Tube Set (CNTS) for continuous therapy, and Controllers and Accessories. The company also operates Aerogen Pharma as a clinical-stage specialty pharmaceutical division focused on inhaled drug/biologic and device combinations.
Differentiator
Problem solved
Functional benefit
Brands
- Aerogen Pharma: US-based clinical-stage specialty pharmaceutical company developing inhaled drug/biologic and device combinations for acute and critically ill patients, including treatments for neonatal respiratory distress syndrome (RDS).
Products and services
- Aerogen Solo Single-patient-use vibrating mesh nebuliser that delivers aerosolised medication across invasive mechanical ventilation, non-invasive ventilation, high-flow therapy, and self-ventilating patient scenarios for up to 28 days intermittent or 7 days continuous use; intended for hospital ICU and acute care use.
- Aerogen Ultra Handheld vibrating mesh nebuliser used in conjunction with the Aerogen Solo to deliver inhalation treatment to spontaneously breathing and emergency department patients.
- Aerogen Go Portable vibrating mesh nebuliser for aerosol drug delivery within the Aerogen product lineup, intended for clinical respiratory therapy use.
- Aerogen Pro Professional-grade vibrating mesh nebuliser within Aerogen's portfolio of acute care aerosol drug delivery devices.
- Aerogen Continuous Nebulisation Tube Set (CNTS) Tube set accessory that enables continuous nebulisation therapy when used with the Aerogen Solo system.
- Aerogen Controllers and Accessories Power controllers and accessories that operate and support the Aerogen vibrating mesh nebuliser product family in clinical settings.
- Aerogen Pharma Drug-Device Combination Products Clinical-stage inhaled drug and biologic/device combination products developed by the wholly owned subsidiary Aerogen Pharma for treatment of neonatal respiratory distress syndrome and other acute respiratory conditions in critically ill patients.
Quantifiable outcome
- 4x more medication delivered to lungs vs jet nebulisers during NIV
- +4 more outcomes
Companies that use Aerogen
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
Aerogen technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Aerogen partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core and regional.
- SynairgencoreStrategic partnership to advance inhaled therapy for severe respiratory infections. Synairgen's SNG001 (inhaled interferon-beta) being evaluated with Aerogen's nebuliser technology in global Phase 2 INVENT clinical study.
- CanSinoBIOcoreLandmark development and commercial supply partnership for world's first inhaled Covid-19 vaccine delivery using Aerogen's vibrating mesh nebuliser technology.
- Nuance PharmacoreAerogen Pharma entered exclusive agreements with Nuance Pharma to advance treatment of respiratory distress syndrome in premature infants in China.
- ANANDIC Medical Systems AGregionalDistribution partnership for Switzerland. ANANDIC (Anesthesia and Intensive Care & Cardiology) is a leading Swiss market company with 3 locations providing customer support and service.
- Grupo MoraviregionalNew distributor partnership for Mexico to expand market presence and customer support in Mexican healthcare market.
- AcertysregionalDistributor partnership for Belgium to support and service Aerogen users in the Belgian market.
- Premier, Inc.coreGroup purchasing organization awarded Aerogen respiratory therapy: medication delivery and bronchial hygiene agreement for US healthcare members.
- VizientcoreVizient awarded Aerogen contract for medication delivery to member healthcare organizations across the US.
- CÚRAMregionalCollaboration with CÚRAM (Centre for Research in Medical Devices) to alleviate acute respiratory failure in COVID patients.
- Tyndall National Instituteregional€300k research collaboration agreement with Tyndall for technology development and research initiatives.
- UNICEFcoreAerogen supports global vaccine equity and neonatal health through UNICEF partnerships and initiatives.
- Bill & Melinda Gates FoundationcorePartnership with Bill & Melinda Gates Foundation for development of low-cost surfactant for premature babies with respiratory distress syndrome.
- DruidregionalContinued partnership with Druid for integrated solutions in respiratory care.
Scale indicators8 records
Recent moves9 records
Expansion highlights7 records
Aerogen competitors and assessment
Company assessmentDirect peers
- PARI Pharma: Specializes in nebuliser systems and inhaled drug delivery for respiratory diseases including cystic fibrosis and COPD. Directly comparable to Aerogen in core product category of aerosol drug delivery, with overlapping hospital and home-care customer bases.
- Omron Healthcare: Major manufacturer of nebuliser devices for asthma, COPD, and respiratory conditions, with both compressor and mesh technologies. Direct competitor in aerosol drug delivery, although Omron is more weighted to home/consumer use than Aerogen's acute-care focus.
- Intersurgical: European manufacturer of respiratory care products including nebulisers and breathing circuits. Direct competitor in hospital aerosol drug delivery with comparable ICU customer base across EMEA.
- Drive DeVilbiss Healthcare: Manufactures respiratory care products including a portfolio of nebulisers for clinical and home use. Competitor in the aerosol drug delivery category with overlapping acute and post-acute care customers.
Broad incumbents
- Philips Respironics: Large incumbent in respiratory care and ventilation offering nebulisers, CPAP/BiPAP, and hospital respiratory solutions. Overlaps with Aerogen in hospital aerosol drug delivery but as part of a much broader portfolio.
- Fisher & Paykel Healthcare: Global leader in respiratory humidification, high-flow therapy, and neonatal care products sold into the same ICU and NICU customers Aerogen serves. Comparable in acute-care hospital channels and increasingly in the high-flow therapy segment adjacent to Aerogen's HF modality.
- Teleflex: Manufactures respiratory care products including nebulisers and aerosol delivery devices used in acute-care hospitals. Sells into the same ICU/critical care channels as Aerogen, with a broader single-use device portfolio.
Emerging players
- Vapotherm: Specializes in high-flow therapy systems for respiratory distress, overlapping with Aerogen's HF modality segment. Sells into the same acute-care hospital channel and increasingly competes for aerosol delivery during high-flow treatment.
- Vectura Group (now Philip Morris International): Develops inhaled drug-device combinations and nebuliser platforms for respiratory disease. Comparable to Aerogen Pharma's inhaled drug/biologic development strategy, especially in dry-powder and smart nebuliser technologies.
Others
- Hamilton Medical: Leading ventilator OEM whose systems are explicitly integrated with Aerogen nebulisers. Highly relevant as an OEM channel partner and a key distribution conduit for Aerogen Solo in ICU settings globally.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Aerogen social profiles
Digital presenceAerogen compliance and trust
Trust signalCompliance3 records
Aerogen financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aerogen leadership team
Management profileNumber of profiles
Profiles2 records
Aerogen subsidiaries and ownership
Company hierarchySubsidiaries1 record
Aerogen funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aerogen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aerogen
What does Aerogen do?
Aerogen designs, manufactures, and sells vibrating mesh nebuliser devices used by hospitals and intensive care units for high-performance aerosol drug delivery across the full respiratory care journey (invasive mechanical ventilation, non-invasive ventilation, high-flow therapy, and self-ventilating patients). Its wholly owned subsidiary Aerogen Pharma develops inhaled drug/device combination products targeting acute and neonatal respiratory conditions.
Is Aerogen a public or private company?
Aerogen is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Aerogen founded?
Aerogen was founded in 1998. It employs 501 to 1,000 people.
Where is Aerogen based?
Aerogen is headquartered in Galway, Ireland, in the Europe region.
How does Aerogen make money?
Two revenue lines are on record. Medical Device Sales - Nebulisers are the primary driver. The others are aerogen Pharma - Drug-Device Combinations.
Who are Aerogen's main competitors?
Direct peers on record are PARI Pharma, Omron Healthcare, Intersurgical and Drive DeVilbiss Healthcare. Broad incumbents are Philips Respironics, Fisher & Paykel Healthcare and Teleflex. Emerging players are Vapotherm and Vectura Group (now Philip Morris International). Hamilton Medical is listed as an others.
Does Aerogen have an API?
No public API is recorded for Aerogen.
What industry is Aerogen in?
Aerogen's product category is Respiratory Care Medical Devices. Its primary akta.pro industry code is HLAHAIAJ, Nebulizers & Aerosol Drug Delivery Systems, with a secondary code of HLAHAGAE, Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories). Its NAICS code is 3391 and its SIC code is 3845.